I don't think that affects the GP point though. If the US is a profit center for pharma, that makes developing drugs more profitable overall, which means more drugs will be developed.
Pharma companies are gamblers. They gamble on the cost of R&D, the market size for the drug, the amount they will be able to charge. The higher the expected value of their profits, the wider variety of drugs look like attractive prospects financially.
Pharma companies are gamblers. They gamble on the cost of R&D, the market size for the drug, the amount they will be able to charge. The higher the expected value of their profits, the wider variety of drugs look like attractive prospects financially.